) subsidiary, has received U.S. Food and Drug Administration
(FDA) approval to sell its diagnostic tool Clone EP1 for the
treatment of breast cancer in the U.S. market. The tool is
already available in Europe.
The antibody named FLEX Monoclonal Rabbit Anti-Human Estrogen
Receptor alpha, Clone EP1, will help to get nearly accurate
status of estrogen receptor (ER) in breast carcinomas, which is
considered to be the most reliable factor to manage a patient's
Clone EP1 was created by Epitomics Inc., the leader in rabbit
monoclonal antibody (RabMAb) technology. Dako collaborated with
Epitomics in 2011 to develop technologies in the field of
anatomic pathology to detect and fight cancer. The company said
that the new antibody will help physicians to provide the most
effective treatment for a particular type of breast cancer.
Currently, the healthcare sector is witnessing a revolution
and anatomic pathology tests are growing in popularity due to the
valuable information they generate. The diagnosis in anatomic
pathology is based on gross, microscopic, chemical, immunologic
and molecular examination of organs, tissues and whole bodies
Agilent had acquired the Danish cancer diagnostics company
Dako for $2.2 billion (on a debt-free basis) last year. Dako
provides antibodies, scientific instruments and software mainly
to cancer-related diagnostic labs and collaborates with drug
companies for the development of methods to identify patients
likely to benefit from certain therapies.
The company is continuously launching new tests and has
collaborated with major companies to develop technologies in the
field of anatomic pathology to fight cancer. Thus, with these
collaborations and the FDA approval for its drugs, Dako may help
Agilent tap the opportunity in the fast-growing healthcare
Agilent's revenues in the first quarter were down sequentially
but up 2.8% year over year to $1.68 billion. Revenue growth was
greatly helped by the Dako acquisition. Earnings per share of 63
cents missed the Zacks Consensus Estimate by 4 cents or 6.0%.
Currently, Agilent has a Zacks Rank #3 (Hold). Other stocks
that have been performing well and are worth considering include
Brocade Communications Systems
), all carrying a Zacks Rank #2 (Buy).
AGILENT TECH (A): Free Stock Analysis Report
To read this article on Zacks.com click here.